Buyback yield (TTM)
4.41%
Shareholder yield (TTM)
6.77%
5Y share count change
-12.8%
Buyback spend (TTM)
$2.85B
Cumulative buybacks
$54.08B
Key takeaways
- Elevance Health (ELV) repurchased about $2.85B of stock over the trailing twelve months.
- Diluted share count is down 12.8% over the last ~5 fiscal years — buybacks are net-shrinking the share base.
- TTM buyback ÷ stock-based-comp ratio of 11.40× — repurchases more than cover SBC dilution.
- Cash buyback spend has compounded at -0.7% per year over the latest 5-year window.
- TTM repurchases used about 58% of free cash flow remaining after dividends.
Dividend & buyback yield over time for Elevance Health (ELV)
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Diluted vs basic shares (annual) for Elevance Health (ELV)
Diluted weighted-average shares are the EPS denominator — a falling count means buybacks are outpacing SBC dilution.
Year-over-year change in diluted shares for Elevance Health (ELV)
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Cash buyback spend over time for Elevance Health (ELV)
Latest: $2.60B
Overview
2025's annual buyback spend for Elevance Health (ELV) came in at $2.60B – declined 10.2% year-over-year.
Elevance Health buyback spend has contracted on net over the period, with a -0.7% compound annual growth rate over 2020–2025 (5 years).
Elevance Health buyback spend peaked at $6.15B in 2007; the latest annual figure is $2.60B in 2025 (57.7% below peak).
The highest annual buyback spend of $6.15B was reported in 2007. The lowest in the available history was $0.00 in 2001.
Elevance Health Buyback Spend 2025: $2.60B
Elevance Health posted buyback spend of $2.60B in 2025, declined 10.2% below 2024.
Elevance Health Buyback Spend 2024: $2.90B
In 2024, Elevance Health reported buyback spend of $2.90B, grew 8.4% from 2023.
Elevance Health Buyback Spend 2023: $2.68B
Elevance Health buyback spend in 2023 was $2.68B, grew 15.5% from 2022.
Elevance Health Buyback Spend 2022: $2.32B
2022's buyback spend for Elevance Health came in at $2.32B, grew 21.9% from 2021.
Elevance Health Buyback Spend 2021: $1.90B
Elevance Health buyback spend in 2021 was $1.90B.
See more financial history for Elevance Health (ELV).
Buyback, SBC & dilution history
Buyback spend, SBC, net dilution effect, and share count.
| 2025 | $2.60B | $276.00M | $2.33B | 3.35% | 0.22B | -4.8% | |
| 2024 | $2.90B | $191.00M | $2.71B | 3.46% | 0.23B | -1.9% | |
| 2023 | $2.68B | $289.00M | $2.39B | 2.43% | 0.24B | -2.2% | |
| 2022 | $2.32B | $264.00M | $2.05B | 1.90% | 0.24B | -1.6% | |
| 2021 | $1.90B | $255.00M | $1.65B | 1.70% | 0.25B | -2.9% | |
| 2020 | $2.70B | $283.00M | $2.42B | 3.43% | 0.25B | -2.3% | |
| 2019 | $1.70B | $294.00M | $1.41B | 2.23% | 0.26B | +2.4% | |
| 2018 | $1.69B | $226.00M | $1.46B | 2.49% | 0.25B | -5.0% | |
| 2017 | $2.00B | $169.60M | $1.83B | 3.47% | 0.27B | -0.1% | |
| 2016 | $67.00M | $164.60M | −$97.60M | 0.18% | 0.27B | -1.8% | |
| 2015 | $1.52B | $148.20M | $1.37B | 4.16% | 0.27B | -4.5% | |
| 2014 | $3.00B | $168.90M | $2.83B | 8.95% | 0.29B | -5.9% | |
| 2013 | $1.62B | $146.00M | $1.47B | 6.22% | 0.30B | -6.5% | |
| 2012 | $2.50B | $146.50M | $2.35B | 13.52% | 0.32B | -11.0% | |
| 2011 | $3.04B | $134.80M | $2.90B | 13.83% | 0.37B | -12.2% | |
| 2010 | $4.36B | $136.00M | $4.22B | 20.80% | 0.42B | -13.9% | |
| 2009 | $2.64B | $153.60M | $2.48B | 10.26% | 0.48B | -7.8% | |
| 2008 | $3.28B | $156.00M | $3.12B | 15.68% | 0.52B | -12.9% | |
| 2007 | $6.15B | $177.10M | $5.97B | 12.88% | 0.60B | -6.2% | |
| 2006 | $4.55B | $246.90M | $4.30B | 9.45% | 0.64B | +2.7% | |
| 2005 | $333.40M | $0.00 | $333.40M | 0.64% | 0.63B | +118.9% | |
| 2004 | $82.20M | $0.00 | $82.20M | 0.23% | 0.29B | +0.7% | |
| 2003 | $217.20M | $0.00 | $217.20M | 2.10% | 0.28B | +16.7% | |
| 2002 | $256.20M | $0.00 | $256.20M | 2.93% | 0.24B | +17.2% | |
| 2001 | $0.00 | $0.00 | $0.00 | — | 0.21B | — |
- 2025$2.60B
- 2024$2.90B
- 2023$2.68B
- 2022$2.32B
- 2021$1.90B
- 2020$2.70B
- 2019$1.70B
- 2018$1.69B
- 2017$2.00B
- 2016$67.00M
- 2015$1.52B
- 2014$3.00B
- 2013$1.62B
- 2012$2.50B
- 2011$3.04B
- 2010$4.36B
- 2009$2.64B
- 2008$3.28B
- 2007$6.15B
- 2006$4.55B
- 2005$333.40M
- 2004$82.20M
- 2003$217.20M
- 2002$256.20M
- 2001$0.00
Buybacks vs stock-based compensation for Elevance Health (ELV)
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 11.40×.
Buybacks vs dividends (share of cash returned) for Elevance Health (ELV)
How Elevance Health splits cash returned to shareholders between dividends and buybacks.
Sector peers by buyback spend
Companies in the same sector as Elevance Health, ranked by their latest buyback spend.
| $5.95B | |
| $5.54B | |
| $5.08B | |
| $4.11B | |
| $980.00M | |
| $216.35M | |
| $0.00 | |
| $0.00 |
- $5.95B
- $5.54B
- $5.08B
- $4.11B
- $980.00M
- $216.35M
- $0.00
- $0.00
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $4.93B (TTM FCF − TTM dividends, clamped at zero).
Frequently asked questions
Data & methodology
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation